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Pre-gestational diabetes mellitus is associated with increased risk of maternal and perinatal
adverse outcomes. This systematic review was conducted to evaluate the effectiveness
and safety of pre-conception care (PCC) in improving maternal and perinatal outcomes.
Methods
Databases from MEDLINE, EMBASE, WEB OF SCIENCE, and Cochrane Library were
searched, including the CENTRAL register of controlled trials, and CINHAL up until March
2019, without any language restrictions, for any pre-pregnancy care aiming at health promo-
tion, glycemic control, and screening and treatment of diabetes complications in women with
type I or type II pre-gestational diabetes. Trials and observational studies were included in the
review. Newcastle-Ottawa scale and the Cochrane collaboration methodology for data syn-
thesis and analysis were used, along with the GRADE tool to evaluate the body of evidence.
Results
The search identified 8500 potentially relevant citations of which 40 reports of 36 studies
were included. The meta-analysis results show that PCC reduced congenital malformations
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risk by 71%, (Risk ratio (RR) 0.29; 95% CI: 0.21–0.40, 25 studies; 5903 women; high-cer-
tainty evidence). The results also show that PCC may lower HbA1c in the first trimester of
pregnancy by an average of 1.27% (Mean difference (MD) 1.27; 95% CI: 1.33–1.22; 4927
women; 24 studies, moderate-certainty evidence). Furthermore, the results suggest that
PCC may lead to a slight reduction in the risk of preterm delivery of 15%, (RR 0.85; 95% CI:
0.73–0.99; nine studies, 2414 women; moderate-certainty evidence). Moreover, PCC may
result in risk reduction of perinatal mortality by 54%, (RR 0.46; 95% CI: 0.30–0.73; ten stud-
ies; 3071 women; moderate-certainty evidence). There is uncertainty about the effects of
PCC on the early booking for antenatal care (MD 1.31; 95% CI: 1.40–1.23; five studies,
1081 women; very low-certainty evidence) and maternal hypoglycemia in the first trimester,
(RR 1.38; 95% CI: 1.07–1.79; three studies; 686 women; very low- certainty evidence). In
addition, results of the meta-analysis indicate that PCC may lead to 48% reduction in the
risk of small for gestational age (SGA) (RR 0.52; 95% CI: 0.37–0.75; six studies, 2261
women; moderate-certainty evidence). PCC may reduce the risk of neonatal admission to
intensive care unit (NICU) by 25% (RR 0.75; 95% CI: 0.67–0.84; four studies; 1322 women;
moderate-certainty evidence). However, PCC may have little or no effect in reducing the
cesarean section rate (RR 1.02; 95% CI: 0.96–1.07; 14 studies; 3641 women; low-certainty
evidence); miscarriage rate (RR 0.86; 95% CI: 0.70–1.06; 11 studies; 2698 women; low-cer-
tainty evidence); macrosomia rate (RR 1.06; 95% CI: 0.97–1.15; nine studies; 2787 women,
low-certainty evidence); neonatal hypoglycemia (RR 0.93; 95% CI: 0.74–1.18; five studies;
880 women; low-certainty evidence); respiratory distress syndrome (RR 0.78; 95% CI:
0.47–1.29; four studies; 466 women; very low-certainty evidence); or shoulder dystocia (RR
0.28; 95% CI: 0.07–1.12; 2 studies; 530 women; very low-certainty evidence).
Conclusion
PCC for women with pre-gestational type 1 or type 2 diabetes mellitus is effective in improv-
ing rates of congenital malformations. In addition, it may improve the risk of preterm delivery
and admission to NICU. PCC probably reduces maternal HbA1C in the first trimester of
pregnancy, perinatal mortality and SGA. There is uncertainty regarding the effects of PCC
on early booking for antenatal care or maternal hypoglycemia during the first trimester of
pregnancy. PCC has little or no effect on other maternal and perinatal outcomes.
Introduction
Globally, the burden of diabetes is increasing. The number of adults living with diabetes is
expected to increase from 429 million to 629 million by the year 2045—which is almost a 50%
increase in the number of the affected population [1]. Furthermore, in low and middle-income
countries, the burden of diabetes is higher among the younger population, including women
in the reproductive age group [2]. If the current situation remains unabated, a substantial
increase in high risk pregnancies complicated with pregestational diabetes will create major
health care problems in low income countries due to the higher mortality and morbidity asso-
ciated with pregestational diabetes compared to non-diabetic pregnancies.
Hyperglycemia in early pregnancy increases the risk of congenital abnormalities by nine-
fold compared to the normoglycemic population [3]. There is a fivefold increase in the rate of
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cardiovascular abnormalities and a twofold increase in the rate of neural tube and urinary
tract defects in infants of mothers with diabetes compared to the background population [4,
5]. Congenital defects and preterm births [6] were the main contributors to the high rate of
perinatal mortality observed in pregnancies complicated by maternal pregestational diabetes
[7, 8].
Many of the serious complications of pregestational diabetes can be averted by implement-
ing preconception care (PCC) [9]. Education about the interaction between diabetes and preg-
nancy, family planning combined with diabetes self-management skills can achieve optimum
glycemic control during early pregnancy, which can reduce rates of congenital abnormalities
and perinatal mortality [10].
Other essential elements of PCC include; folic acid supplementation [11], lifestyle modifica-
tion (weight reduction, smoking cessation), multidisciplinary medical care (endocrinologist,
obstetrician, dietitian and midwives specialized in diabetes), and substituting teratogenic med-
ications for safer ones [12].
Despite the proven clinical value and cost-effectiveness of PCC [13], there is low uptake of
the service in some communities and lack of it in others. Most pregnancies are unplanned,
which makes PCC unfeasible for almost 40% of women with pregestational diabetes [14]. In
addition, the deprived socioeconomic status in low income countries plays a part in access and
utilization of PCC [15], which puts a considerable proportion of women with diabetes at risk
of adverse pregnancy outcomes.
Since the publication of our last systematic review on the effectiveness of PCC in improving
maternal and perinatal outcomes, many studies have been published to investigate different
interventions and outcomes of PCC [9, 16]. Additionally, with the increased recognition of the
importance of evaluation of the body of evidence a grading tool, Grading of Recommendations
Assessment, Development and Evaluation (GRADE), has been introduced to facilitate evi-
dence-based decision making for interventions in clinical medicine and health policy [17].
The objectives of this systematic review are to assess the effectiveness of PCC comprehen-
sively in improving maternal and perinatal outcomes and to evaluate the grade of the body of
evidence for each outcome.
Methods
Search methods
A structured literature search was undertaken to review all the literature published up to
March 2019. The search strategy was developed with the help of library and information
retrieval specialist. We searched the following databases: MEDLINE, EMBASE, WEB OF SCI-
ENCE, CINHAL and Google Scholar; (For full search strategy, see S1 File). Additionally, bibli-
ographies of retrieved articles were manually searched for potentially relevant papers. No
language or date restrictions were applied in the search.
Study selection
The following criteria were applied for eligibility:
• Randomized and quasi-randomized controlled trials, cluster-randomized trials, and obser-
vational (cohort, cross-sectional and case control) studies were eligible for inclusion.
• Studies and trials which compared the frequency of maternal and perinatal adverse out-
comes in women with diabetes who received PCC with those who did not receive PCC.
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• Women of reproductive age with pregestational diabetes type 1 or type 2 diabetes mellitus
who were not pregnant at the time of intervention.
• PCC interventions including (i.e. either as sole intervention or in combination):
• Glycemic control by insulin and/or diet and/or oral hypoglycemic drugs.
• Women counselling and/or education about diabetes complications during pregnancy, the
importance of glycemic control and self-monitoring of blood glucose level.
• Preconception screening and treatment of complications of diabetes
• The use of contraception until optimization of glycemic control is achieved
• Intake of multivitamin or folic acid in the preconception period.
• Physical exercise and/or weight control.
• Studies reporting maternal and neonatal outcomes as follows:
Maternal outcomes:
• Hemoglobin A1c (HbA1c) level in the first trimester of pregnancy
• Gestation age (GA) at the time of the first visit to antenatal care clinic (booking visit)
• Miscarriage or termination of pregnancy due to congenital abnormalities
• Induction of labor due to maternal complications of diabetes
• Delivery by cesarean section (CS) or instrumental delivery
• Maternal hypoglycemia in the first trimester
Neonatal outcomes:
• Preterm delivery
• Congenital malformations related to maternal diabetes
• Perinatal mortality (stillbirth and neonatal death)
• Birth trauma
• Admission to neonatal intensive care unit (NICU)
• Respiratory distress syndrome (RDS)
• Macrosomia (birth weight� 4 kg for term infants or large for gestational age (LGA)birth
weight� 90th percentile for the gestation age)





We screened titles and abstracts of all the potential studies identified as a result of the search
by two reviewers independently. Disagreements were resolved through discussion or after con-
sultation with a third reviewer when needed.
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Articles with the criteria below were excluded from the review:
• Did not contain a complete description of the study or study population
• Did not report original data (commentary, review or editorial) or reports of conference pro-
ceedings or abstracts when complete data could not be retrieved from the authors
• Participants were not women with pregestational diabetes or were pregnant at the time of
intervention
• Did not assess impact of a PCC intervention
• Did not include comparatives arms.
Then the full-text papers were retrieved, and potentially relevant studies were assessed inde-
pendently by two authors for eligibility by application of the inclusion/exclusion criteria. The
review was registered in PROSPERO (registration number CRD42019114336) [18].
Data extraction
The data were subsequently extracted from included studies by two reviewers using a purpose-
fully designed data extraction form. The reviewers were not masked to the articles’ authors,
journals, or institutions. The data extracted were: country and year of publication, settings,
study design, study duration, study population details of intervention/s and control, and out-
comes. When information regarding any of the above was unclear, the authors were contacted
to provide the missing details. Any disagreement on value or type of data extracted between
reviewers was resolved through discussion or by consulting a third reviewer.
Quality assessment
Assessment of risk of bias. Two reviewers independently assessed the risk of bias for each
cohort/ case control study using The Newcastle-Ottawa Scale (NOS) [19]. The criteria assessed
for cohort studies were: participants’ selection, comparability of groups and assessment of out-
come. While participants’ selection, comparability of groups, and exposure criteria were used
to assess the case-control studies. The maximum number of stars awarded for any study were
nine: four stars awarded for selection of participants (exposed and non- exposed), ascertain-
ment of exposure and temporal relation between exposure and outcome, two stars were
awarded for comparability, if analysis controlled for confounding factors, and three stars were
awarded for outcomes if the length of follow up was adequate, with no attrition bias, and if the
outcomes were assessed independent of exposure. Studies at “high risk of bias” score less than
six stars or scores no stars in comparability domain irrespective of the number of stars scored.
Any difference in grading of studies was reconciled by discussion or by involving a third
reviewer. For randomized controlled trials, we used the Cochrane tool for bias assessment
[20].
Overall risk of bias for outcomes. We made explicit judgements about whether studies
included in the meta-analysis of each of the main outcomes, were at high risk of bias according
to the NOS criteria. We assessed the likely magnitude and direction of the bias and whether
the likelihood of having an impact on the findings was of any significance.
Publication bias. We assessed the presence of publication bias using Funnel Plots of effect
size against standard error for each meta-analysis that included ten or more studies according
to Cochrane collaboration methodology. Three analyses were eligible for publication bias
assessment including: the effect of PCC on congenital malformations (25 studies), HbA1C (24
studies) and perinatal mortality (ten studies). The vertical axis of the plot represents the
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standard error, while the horizontal axis represents the logarithmic scale of risk ratio for
dichotomous variables in case of congenital malformations and perinatal mortality. In the case
of continuous variables, as in HbA1c, the horizontal axis represents the standardized mean dif-
ference. Furthermore, we assessed selective reporting in all outcomes [20].
Assessment of the quality of the evidence. The overall quality and strength of evidence
for the main outcomes were assessed using the GRADE approach [21]. We created a ’Sum-
mary of findings’ tables for the main outcomes of the review. The body of evidence is down-
graded from ‘high quality’ by one level for serious (or by two levels for very serious)
limitations depending on assessments of risk of bias, indirectness of evidence, inconsistency,
imprecision of effect estimates or potential publication bias. Subsequently, the quality of evi-
dence was graded as ‘high’, ‘moderate’, ‘low’ or ‘very low’ certainty. Evidence derived from
observational studies receive an initial grade of ‘low’, however, we upgraded the quality of evi-
dence when there was a large magnitude of effect (RR>2 or RR<0.5, in the absence of plausi-
ble confounders) [21]. We downgraded scores for risk of bias (weight of studies show risk of
bias as assessed by low NOS<6), inconsistency (unexplained heterogeneity), indirectness of
evidence (presence of factors that limit the generalizability of the results), imprecision in the
pooled risk estimate (the 95% CI for risk estimates are wide or cross a minimally important
difference of 10% for benefit or harm (RR 0.9–1.1)), and publication bias (evidence of small-
study effects) [21]. We used the GRADEpro tool in order to create the ’Summary of findings’
tables [22]. We assessed the quality of the body of evidence relating to the following outcomes
for the main comparison, PCC versus no PCC; 1) Congenital malformations 2) HbA1c in the
first trimester of pregnancy 3) Perinatal mortality 4) Preterm delivery 5) Maternal hypoglyce-
mia 6) Gestational age at booking for antenatal care.
We produced a summary of the intervention effect using the GRADE approach, a measure
of quality for each of the above outcomes.
Data synthesis. A statistical analysis using RevMan 5 software (RevMan 2014) was carried
out [23]. We used the fixed-effect model to conduct meta-analyses. The pooled statistics was
reported as either relative risk (RR) for categorical variables, or mean difference (MD) for contin-
uous variables in the comparison between the intervention and control groups with 95% confi-
dence intervals (CI). Heterogeneity was quantified in each meta-analysis using the Tau2, I2 and
Chi2 statistics [24]. We regarded heterogeneity as substantial if I2 was� 50% and either Tau2 was
greater than zero, or there was a low p value (less than 0.10) in the Chi2 test for heterogeneity.
We conducted sensitivity analyses by excluding studies with high risk of bias from the met-
analysis for the main review outcomes. We conducted sensitivity analysis for two maternal
outcomes which are gestation age at the first antenatal visit and first trimester HBA1c level, in
addition to five neonatal outcomes, including: congenital malformations, preterm delivery,
perinatal mortality, SGA, and admission to NICU.
Differences between the protocol and the review. The authors decided to utilize the
modified version of NOS proposed by the Agency for Healthcare Research and Quality
(AHRQ), U.S. Department of Health and Human Services [25, 26] as it was more rigorous,
robust, and user-friendly than the original version proposed by the University of Ottawa [19].




Our initial search identified 8500 potentially relevant citations of which 76 full text articles
were reviewed (Fig 1). We identified 40 reports of 36 studies for inclusion in the analysis.
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Among these reports, three articles described the same cohort study with two interim [27, 28]
and one final report [29], one study reported the outcomes of the same cohort in two articles
[30, 31] and two articles reported the outcomes of one cohort with one interim [32] and one
final report [33].
Thirty-six studies were excluded because: they did not meet the inclusion criteria, or were
review articles, data were not extractable in three studies, and one report was excluded because
of co-intervention applied at national level [34].
Study characteristics
Participants. The main characteristics of included studies are summarized in Tables 1–3.
There were 36 included studies conducted through March 2019, all of which were conducted
in high income countries [35]. Of the included studies 18 were prospective cohort studies [31,
36–52], 16 were retrospective cohort studies [29, 32, 33, 49, 53–65], one was a trial [66], and
one was a case control study [67]. The number of participants of cohort studies were 8199
women, among whom 3213 received PCC followed by antenatal care, whilst 4986 only
received antenatal care. There were 24 participants in the case control study [67] and 180
Fig 1. Process of selection of the studies for the systematic review (PRISMA flow chart).
https://doi.org/10.1371/journal.pone.0237571.g001
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Table 1. Characteristics of included cohort studies.
Serial
No.




175 women with (DM-I and DM-II)
NO-PCC:
260 women with (DM-I and DM-II)
PCC included:
• Educational delivered by health care of professionals,
• Assessment of diabetes complications,
• Advice regarding blood glucose optimization,
• Dietary modification,












27 women with (DM-I and DM-II)
NO-PCC:
347 women with (DM-I and DM-II) received care
after conception
PCC included:
• A multidisciplinary team approach to care (physicians, Diabetes educators, dietitians and social workers),
• Comprehensive education,
• Active self- management (e.g. self-glucose monitoring, home testing for ketone- urea, insulin injection techniques),
• Routine maternal care elements and laboratory tests,







3 Damm (1989) Denmark
[36]
PCC:
197 women with (DM-I)
NO-PCC:
61 women with (DM-I)
PCC included:
• Optimization of diabetic control at the time of conception and nidation and during the first trimester,
• Pregnancy planning and contraceptive guidance.
PCC:
First trimester HbA1c: 7.1 ± SD




First trimester HbA1c: 7.3 ± SD






59 women with (DM-I)
NO-PCC:
35 women with (DM-I)
PCC included:
• Insulin and dietary glycemic control,
• Advice on contraception,
• Screening for diabetes complications.
PCC:
x First trimester HbA1c:










149 women with (DM-I and DM-II)
NO-PCC:
265 women with (DM-I and DM-II)
PCC included:
• Patient education,
• Full medication review,
• Assessment and treatment of diabetes complications and thyroid status.
• Folic acid supplement,
• Intensive glucose monitoring with a target HbA1c of less than 6.1%,
• Dietary advice and Pregnancy planning.
PCC:
First trimester HbA1c: 6.8 ± SD









Serious adverse outcome: (3/
149)
Shoulder dystocia: (0/149)








First trimester HbA1c: 7.7 ± SD









Serious adverse outcome: (24/
265)
Shoulder dystocia: (6/265)







6 Cyganek (2010) Poland
[58]
PCC:
116 women with (DM-I)
NO-PCC:
153 women with (DM-I)
PCC included:







7 Cyganek (2016) Poland
[64]
PCC:
210 women with (DM-I)
NO-PCC:
313 women with (DM-I)
PCC included:
• Glycemic control,
• Assessment of diabetes complications.
PCC:
First trimester HbA1c: 6.4 ± SD
1.1 (N = 210)
NO-PCC:
First trimester HbA1c: 7.5 ± SD
1.5 (N = 313)
(Continued)
PLOS ONE Preconception care of mothers with diabetes: Systematic review and meta-analysis








12 women with (DM-I)
NO-PCC:
35 women with (DM-I)
PCC included:
• Glycemic control,
• Assessment of diabetes complications.
PCC:
First trimester HbA1c: 7.9 ± SD










First trimester HbA1c: 9.6 ± SD









9 Evers (2004) Netherland
[47]
PCC:
271 women with (DM-I)
NO-PCC:
52 women with (DM-I)
PCC included:
• Planned pregnancy,
• Folic acid supplementation,
• Glycemic control.
PCC:















185 women with (DM-I)
NO-PCC:
437 women with (DM-I)
PCC included:








11 Galindo (2006) Spain[48] PCC:
15 women with (DM-I and DM-II)
NO-PCC:




• Self-monitoring of blood glucose.
PCC:














66 women with (DM-I and DM-II)
NO-PCC:
119 women with (DM-I and DM-II)
PCC included:
• Intensive insulin therapy,























13 Goldman (1986) Israel
[53]
PCC:
44 women with (DM-I)
NO-PCC:
31 women with (DM-I)
PCC included:
• Assessment of diabetic complications,
• Contraception advice,
• Glycemic control and dietary advice.
PCC:
First trimester HbA1c:
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Study ID Participants Intervention Outcomes
14 Gunton (2000) Australia
[57]
PCC:
24 pregnancies (some participants had more than
one pregnancy) with (DM-I and DM-II)
NO-PCC:
69 pregnancies (some participants had more than
one pregnancy) with (DM-I and DM-II)
Total N = of women: 61
PCC included:
• Pregnancies planning by optimizing glycemic control before conception (i.e. intensive insulin regimen treatment and tested the blood
glucose frequently).
PCC:
First trimester HbA1c: 6.6 ± SD
2.8 (N = 24)
CS delivery: (3/24)
NO-PCC:
First trimester HbA1c: 8.4 ± SD
5.4 (N = 69)
CS delivery: (33/69)
15 Gunton (2002) Australia
[44]
PCC:
19 pregnancies (some participants had more than
one pregnancy) with (DM-I and DM-II)
NO-PCC:
16 pregnancies (some participants had more than
one pregnancy) with (DM-I and DM-II)
Total Number of women:31
PCC included:
• Pregnancies planning by optimizing glycemic control before conception
PCC:
First trimester HbA1c: 5.5 ± SD






First trimester HbA1c: 6.5 ± SD








99 women with (DM-I)
[44 treated with Aspart Insulin
55 women treated with Human Insulin]
NO-PCC:
223 women with (DM-I)
[113 treated with Aspart Insulin
110 women treated with Human Insulin]
PCC included:
• Insulin treatment with either Aspart or human insulin.
PCC:
x First trimester HbA1c:
6.24 ± SD 0.69 (N = 99)
NO-PCC:
x First trimester HbA1c:




24 women with (DM-I and DM-II)
NO-PCC:
36 women with (DM-I and DM-II)
PCC included:
Pregnancy programming: -
• Pre-conceptional specialized consultation,
• Intensification of glycemic self-monitoring,
• Optimization of insulin therapy of a preconception HbA1c close to 6%.
PCC:
First trimester HbA1c:











24 women with (DM-I)
NO-PCC:
74 women with (DM-I)
PCC included:
• Education and counselling,
• Glycemic control,









19 Holmes (2017) United
Kingdom [51]
PCC:
58 women with (DM-I and DM-II)
NO-PCC:
114 women with (DM-I and DM-II)
PCC included:
• Viewing DVD about preconception counselling.
PCC:
First trimester HbA1c: 6.7 ± SD





GA at booking(week): 8.3 ± SD





First trimester HbA1c: 7.4 ± SD





GA at booking(week): 8.3 ± SD
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21 women with (DM-I)
NO-PCC:









GA at booking(week): 6.7 ± SD
1.8 (N = 21)
Congenital malformations: (0/
21)







GA at booking(week): 11.1 ± SD
5.3 (N = 40)
Congenital malformations: (3/
40)




21 Jensen (1986) Denmark
[68]
PCC:
9 women with (DM-I)
NO-PCC:
11 women with (DM-I)
PCC included:
• Glycemic control through continuous subcutaneous insulin infusion and conventional treatment. Initiated two months prior to
conception.
PCC:
First trimester HbA1c: 6.9 ± SD
0.2 (N = 9)
NO-PCC:
First trimester HbA1c: 7.2 ± SD




71 women with (DM-I and DM-II)
NO-PCC:
150 women with (DM-I and DM-II)
PCC included:












96 women with (DM-I)
NO-PCC:
49 of women with (DM-I)
PCC included:
• Pregnancy Planning
• Optimizing glycemic control
• Medications and screening of other health problems.
PCC:
First trimester HbA1c:





























84 women with (DM-I and DM-II)
NO-PCC:
110 women with (DM-I and DM-II)
PCC included:
• Glycemic and dietary control,
• Education,
• Self-monitoring,










181 women with (DM-I and DM-II)
NO-PCC:
495 women with (DM-I and DM-II)
PCC included:
• Glycemic control,
• Folic acid supplementation,
• Smoking cessation,
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70 women with (DM-I)
NO-PCC:
394 women with (DM-I)
PCC included:
• Insulin treatment which was continuous subcutaneous infusion and multiple daily injection.
PCC:
First trimester HbA1c: 6.9 ± SD






GA at booking(week): 6 ± SD 2
(N = 70)
NO-PCC:
First trimester HbA1c: 7.8 ± SD











43 women with (DM-I and DM-II)
NO-PCC:
108 women with (DM-I and DM-II)
PCC included:
• Pregnancy planning,
• Counseling delivered by a diabetes specialist,
• Glycemic control by making necessary changes in pharmacotherapy,




6.15 ± SD 0.82 (N = 43)
NO-PCC:
x First trimester HbA1c:




28 women with (DM-I)
NO-PCC:





First trimester HbA1c:8.5 ± SD




GA at booking(week): 5.5 ± SD
0.2 (N = 28)
NO-PCC:
First trimester HbA1c: 10 ± SD
0.32 (N = 71)
Congenital malformations: (1/
71)
GA at booking(week): 6.8 ± SD





14 women with (DM-I)
NO-PCC:




• Blood glucose self-monitoring.
PCC:
First trimester HbA1c: 9.8 ± SD





13.7 ± SD 3.3 (N = 7)
Congenital malformations: (2/
7)
30 Steel (1982 & 1990)
United Kingdom[32, 33]
PCC:
143 women with (DM-I)
NO-PCC:






First trimester HbA1c: 8.4 ± SD
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Study ID Participants Intervention Outcomes




110 women with (DM-I)
NO-PCC:
180 women with (DM-I)
PCC included:
• Glycemic control,




First trimester HbA1c: 5.9 ± SD
0.9 (N = 110)
GA at booking(week): 6.6 ± SD










# Perinatal mortality: (1/110)
NO-PCC:
First trimester HbA1c: 6.6 ± SD
1.2 (N = 180)
GA at booking(week): 8.3 ± SD














62 women with (DM-I and DM-II)
NO-PCC:
123 women with (DM-I and DM-II)
PCC included:












52 women with (DM-I and DM-II)
NO-PCC:
109 women with (DM-I and DM-II)
PCC included:
• HbA1c monitoring in each trimester,
• Insulin treatment,
• Pregnancies planning,
• Diabetes management by a diabetes (i.e. endocrinologists or general physicians with a special interest in diabetes),
• Following up throughout pregnancy with the involvement of dietitians and diabetes educators.
PCC:
x First trimester HbA1c:





x First trimester HbA1c:







455 women with (DM-I)
NO-PCC:
292 women with (DM-I)
PCC included:
• Pregnancy planning,
• Pre-pregnancy counselling (as structured advice about maintaining good blood glucose control and healthy lifestyle (with respect to
diet, exercise, BMI, smoking status and alcohol consumption) before trying to become pregnant, including the need to take folate
supplements.
PCC:
First trimester HbA1c: 7.0 ± SD










First trimester HbA1c: 7.5 ± SD









DM-I: Diabetes Mellitus type I, DM-II: Diabetes Mellitus type II, GA: Gestational Age, GWG: Gestational Weight Gain, HbA1c: Glycated Haemoglobin, LGA: Large
for Gestational Age, NICU: Neonatal Intensive Care Unit, NO-PCC: No Preconception Care, PCC: Preconception Care, RDS: Respiratory Distress Syndrome, SGA:
Small for Gestational Age
x Calculated mean
~ LGA and macrosomia
# sum of stillbirth and neonatal death
https://doi.org/10.1371/journal.pone.0237571.t001
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pregnancies in the trial [66]. Most of studies did not report the differences in the outcomes
among type 1 versus type 2 diabetes, subsequently, we could not conduct the analysis sepa-
rately for each type of diabetes.
Interventions. The PPC in all the cohort studies included control and self-monitoring of
blood glucose except for one study which was designed to examine the effectiveness of pre-
pregnancy counseling on perinatal outcomes [40]. In addition to glycemic control, ten studies
included screening and treatment of complications of diabetes in the PPC program [29, 42, 45,
50, 53, 55, 56, 58, 61, 62]. Eleven studies (12 reports) reported comprehensive PCC program
including control and self-monitoring of blood glucose in addition to any combination of the
following: folic acid supplementation, diet and exercise, smoking cessation, alcohol withdrawal
advice, and discontinuation of teratogenic drugs [31, 38, 47, 50–52, 58–61, 63].
Outcomes measure. In this review, a total of 14 outcomes were reported in the cohort
studies, including five maternal outcomes: HbA1c in the first trimester, CS delivery, miscar-
riage, GA at first antenatal booking, and maternal hypoglycemia during the first trimester.
There were nine neonatal outcomes (congenital malformations, perinatal mortality, preterm
Table 3. Characteristics of included RCT studies.




94 women with 135 pregnancies in the intensive treatment
group and 86 women with 135 pregnancies in the
conventional treatment group
Intensive glycemic control (IGC) (multiple daily
insulin injections or continuous infusion pump and
self-monitoring)
PCC:











At conception HbA1c: 8.1








NO-PCC: No preconception care, PCC: pre-conception care, HbA1c: Glycated Haemoglobin.
https://doi.org/10.1371/journal.pone.0237571.t003
Table 2. Characteristics of included case control study.













First trimester HbA1c: 8.29±1.32
Congenital malformations: 2/12
Macrosomia: 4/12
NO-PCC: No preconception care, PCC: pre-conception care, HbA1c: Glycated Haemoglobin.
https://doi.org/10.1371/journal.pone.0237571.t002
PLOS ONE Preconception care of mothers with diabetes: Systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0237571 August 18, 2020 14 / 32
Table 4. Risk of bias assessment of the included studies.
Study Selection Comparability Outcome Total Risk of Bias assessment/Notes








Boulot 2003[45] � � � � � � � � � 9 Low risk
Cousins 1991
[37]
� � � � unclear unclear � � unclear 6 High risk
No comparability
Damm 1989[36] � � � � unclear unclear unclear � 5 High risk
Unclear group comparability
Dicker 1988[55] � � � � � � � � 8 Low risk
Egan 2016[50] � � � � � � � � 8 Low risk
Cyganek 2010
[58]
� � � � � � � � � 9 Low risk
Cyganek 2016
[64]
� � � � � � � � 8 Low risk
Dunne 1999 [56] � � � � � � � 7 High risk
The study was an audit, groups
were different in smoking, no
statistical adjustment done.
Evers 2004[47] � � � � Unclear Unclear � � � 7 High risk
Confounding factors such as
smoking, education level and social
class were not examined. The
results of HbA1c during the first
trimester were not available for




� � � Unclear Unclear � � 5 High risk
no description of the possible
confounding factors or adjustment
Galindo 2006
[48]
� � � � unclear unclear � � � 7 High risk
It is unclear if factors influencing
the outcome were similar in both





� � � � unclear � � � 7 Low risk
Goldman 1986
[53]
� � � � Unclear � � � 7 High risk
Difference in smoking and BMI
between the groups not assessed
Gunton 2000
[57]
� � � � � � � 7 Low risk
Gunton 2002
[44]
� � � Unclear Unclear � � � 6 High risk
Difference in the duration of
diabetes between the groups not
controlled for
Gutaj 2013[61] � � � � � � � 7 Low risk
Heller 2010 [49] � � � � � � � � � 9 Low risk
Hiéronimus
2004[46]
� � � Unclear Unclear � � � 6 High risk
no description of the possible
confounding factors or adjustment
Herman 1999
[42]
� � � � Unclear � � 6 High risk
The groups are different in
duration of diabetes other
confounders not addressed, no
adjustment
Holmes 2017[51] � � � � � � � 7 Low risk
(Continued)
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delivery, macrosomia/LGA, SGA, neonatal hypoglycemia, admission to NICU, RDS and
shoulder dystocia). The most frequently reported outcomes were HbA1c in the first trimester
(24 studies) [31, 32, 36, 39, 44, 46–57, 60–65, 68] and congenital malformations (25 studies)
[29, 31, 32, 36–48, 50–54, 56, 59, 62, 65]. Fourteen studies examined the reduction in CS
Table 4. (Continued)
Study Selection Comparability Outcome Total Risk of Bias assessment/Notes








Jaffiol 2000[43] � � � � � � � � 8 Low risk
Jensen 1986[68] � � Unclear Unclear � � 4 High risk
Differences in the severity of
diabetes, five of the 11 control
women were treated in the diabetic
clinic in the hospital before
pregnancy so they knew about the
importance of glycemic control
Kallas-Koeman
2012[60]
� � � � � � � � � 9 Low risk
Kekäläinen 2016
[65]
� � � � � � � � 8 Low risk
Kitzmiller 1991
[38]
� � � Unclear Unclear � � � 6 High risk Unclear if there is
difference between the groups.
Murphy 2010
[59]
� � � � � � � � � 9 Low risk
Neff 2014[63] � � � � � � � � 8 Low risk
Rosenn 1991[39] � � � Unclear Unclear � � 5 High risk
52% lost to follow up, different
baseline characteristics including
duration of diabetes, age,
complications of diabetes
Rowe 1987 [54] � � Unclear Unclear � � 4 High risk
no description of the possible
confounding factors or adjustment
Steel 1982, 1990
[32, 33]
� � � � � � � � 7 Low risk
There is no significant clinical age
difference between the groups.
However, there is different number
of smokers. No regression analysis
was done to address this difference
Temple a & b
2006 [30, 31]
� � � � � � � � � 9 Low risk
Willhoite 1993
[40]
� � unclear � � � 5 High risk
Base line characteristics of the two
groups were significantly different
in age, duration of diabetes and
smoking. The two groups did not
receive the same antenatal intra-
partum and postnatal care.
Wong 2013 [62] � � � � � � � � 8 Low risk
Wotherspoon
2017[52]
� � � � � � � � 8 Low risk
Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The number of stars represents the risk of bias; the maximum number of stars is nine, studies were
classified as “low risk of bias” if they received a score of six stars or more, along with at least one star in the comparability domain. Studies at “high risk of bias” scored
less than six stars or scored no stars in comparability domain, irrespective of the number of stars scored.
https://doi.org/10.1371/journal.pone.0237571.t004
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delivery in women who received PCC compared to those who did not [31, 41, 43, 44, 50–53,
56–59, 63, 65]. Eleven studies compared the miscarriage rate between the two groups [31, 39,
41–43, 50, 51, 55, 59, 63, 65].
Perinatal mortality [31, 40, 41, 43, 45, 50, 52, 56, 59, 62] and preterm delivery [31, 41, 43,
50, 56, 58, 59, 63, 65] were reported in ten and nine studies respectively, while LGA, macroso-
mia [31, 44, 50–52, 56, 59, 63, 65] SGA [41, 50, 52, 56, 59, 63], and neonatal hypoglycemia [41,
43, 50, 53, 65] were reported in nine, six and five studies respectively. Admission to NICU
[50–52, 56], and neonatal RDS [41, 43, 53, 65] were reported in four studies. The least reported
outcomes were maternal hypoglycemia in three studies (all reported results among type 1 dia-
betes) [31, 33, 51] and shoulder dystocia in two studies [50, 65].
Assessment of the methodological quality of the included studies. We used the NOS
Form for Cohort Studies to determine the level of bias of cohort studies included in this review
(Table 4). 21 studies were determined to be at a low risk of bias [30–33, 41, 43, 45, 49–52, 55,
57–65], while 15 studies were judged to be at a high risk of bias [27–29, 36–40, 42, 44, 46–48,
53, 54, 56, 68]. Some of the studies at a high risk of bias were initially designed to assess aspects
of PPC other than its effectiveness in improving maternal and perinatal outcomes, hence the
poor methodological design when assessed with the NOS [40, 42, 56].
The cohort studies included in this review (Table 1) had adequate description of partici-
pants including comparison between the PPC group and the control group regarding some
confounding factors such as the duration of diabetes and frequency of renal and vascular com-
plications. However, most studies did not address the effect of the confounding factors on the
outcomes except for ten studies (11 reports) which used regression analysis to evaluate the
independent effect of the PPC [31, 45, 51, 52, 57–60, 63, 65]. In most cohort studies, blinding
of the control group was adequate because they were recruited after the inception of pregnancy
while attending the antenatal care. In four studies, [33, 38, 49, 50] blinding was inadequate as
the control groups were invited to participate in the PCC program and hence were informed
about it. All participants received the same antenatal and postnatal care except for six studies
[42, 47, 49–52] where participants were followed up in different health settings. In all cohort
studies, the compliance of participants to follow up was adequate except for Rosenn et al [39]
where 52% of the PCC group were lost to follow-up, and Jensen et al [68] where 3 out of 11
participants in control group did not comply with study protocol as they rejected the self-glu-
cose monitoring. The assessors of the outcomes were not blinded to the participants’ alloca-
tion; however, we do not believe this would have introduced bias due to the objective nature of
the outcomes in this review.
One case control study was included in this review [67]. The study encompassed a small
sample size which included 12 cases each for cases and control. Both recall bias and detection
bias cannot be excluded.
One trial was included in this review [66] (Table 3). The design of the trial was not clear;
neither the method of randomization nor the allocation concealment was described. In addi-
tion to that, lack of blinding introduced bias because both groups were aware of the impor-
tance of the glycemic control and the complications of diabetes during pregnancy.
Effects of intervention. Fourteen outcomes were identified after examining all the stud-
ies; meta-analysis was possible for 34 cohort studies with 8199 participants.
Gestational age at booking for antenatal care. The results of the meta-analysis on the effect
of PCC on the early booking for antenatal care showed that women who attended PCC booked
approximately ten days earlier for antenatal care (MD 1.31; 95% CI: 1.40–1.23); five studies,
1081 women very low-certainty evidence)) (Fig 2) (Table 5). The quality of evidence was
downgraded from low-grade (observational study) to very low-grade due to the high risk of
bias in the study with the largest weight [39] and high unexplained heterogeneity (Table 6).
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Congenital malformations. The result of the meta-analysis on the effect of PCC on congeni-
tal malformations suggested that PCC resulted in a large reduction in congenital malforma-
tions (RR 0.29; 95% CI: 0.21–0.40, 25 studies; 5903 women; high-certainty evidence) (Fig 3)
(Table 5). We considered the body of evidence for the effect of PCC on the reduction of con-
genital malformations to be high quality mainly due to the large effect size with precise and
narrow confidence intervals, consistency of direction of effect throughout most of the included
studies, no indirectness of evidence, and no heterogeneity or publication bias. Bias in the
included studies was considered moderate (59% of the participants were from studies at low-
risk of bias) (Fig 3, Table 6).
HbA1c. Meta-analysis of 24 studies which reported HbA1c showed that PCC likely results
in a reduction in HbA1c in the first trimester of pregnancy by an average of 1.27%; (MD 1.27;
95% CI: 1.33–1.22; 4927 women; moderate-certainty evidence) (Fig 4) (Tables 5 & 6). We con-
sidered bias in the included studies low (77% of the participants were from studies at low risk
of bias) (Fig 4, Table 6), while heterogeneity can be explained by long span of time between the
Fig 2. The mean gestational age at the time of the first antenatal visit from five studies of women with pre-
existing diabetes mellitus who did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g002
Table 5. Pooled estimates effect of preconception care.
Outcome No of Studies No of Participants Effect estimate Risk Ratio [95% CI]
Congenital malformations 25 5903 0.29 [0.21, 0.40]
Maternal hypoglycemia 3 686 1.38 [1.07, 1.79]
Preterm delivery 9 2414 0.85 [0.73, 0.99]
Perinatal mortality 10 3071 0.46 [0.30, 0.73]
Small for gestational age 6 2261 0.52 [0.37, 0.75]
Admission to neonatal intensive care unit 4 1322 0.75 [0.67, 0.84]
Cesarean section delivery 14 3641 1.02 [0.96, 1.07]
Miscarriage 11 2698 0.86 [0.70, 1.06]
Large for gestational age / macrosomia 9 2787 1.06 [0.97, 1.15]
Neonatal hypoglycemia 5 880 0.93 [0.74, 1.18]
Respiratory distress syndrome 4 466 0.78 [0.47, 1.29]
Shoulder dystocia 2 530 0.28 [0.07, 1.12]
Mean Difference [95% CI]
Gestational age at booking for antenatal care 5 1081 -1.31 [-1.40, -1.23]
HbA1c in the first trimester 24 4927 -1.27 [-1.33, -1.22]
CI: Confidence Interval.
https://doi.org/10.1371/journal.pone.0237571.t005
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first and the last study (1982 and 2017), during which time many innovations in the manage-
ment of diabetes has occurred with substantial reduction in the target level of HbA1c. The
Table 6. Summary of findings table.
[Preconception care] compared to [no preconception care] or [routine care] for [improving maternal and perinatal outcomes]
Patient or population: [improving maternal and perinatal outcomes]
Setting: Hospital setting
Intervention: [Preconception care]
Comparison: [no preconception care] or [routine care]


















up: mean 9 months a






⊕⊕⊕⊕ HIGH [Preconception care] results in
large reduction in congenital
malformations.
Perinatal mortality
follow up: mean 9
months b








[Preconception care] results in




mean 9 months c
The mean gestational
age at booking was 8.5
Weeks
mean 1.31 Weeks fewer






[Preconception care] may result
in a slight reduction in
gestational age at booking.
Hemoglobin A1c
(HbA1c) follow up:
mean 9 months d
The mean hemoglobin
A1c was 8.3%
mean 1.32% lower (1.34







results in a reduction in HbA1c.
Maternal hypoglycemia
follow up: mean 9
months e














up: mean 9 months f











results in a slight reduction in
preterm delivery.
Small for gestational age
follow up: mean 9
months g









small for gestational age.
�The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI = Confidence interval; RR = Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Upgraded to high because of large effect size, consistency of direction of effect, no indirectness of evidence, and no heterogeneity or publication bias.
b Upgraded to moderate due to the narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, and low risk of bias, no heterogeneity or
publication bias.
c Downgraded to very low-grade due to the high risk of bias in the study with the largest weight [39] and high unexplained heterogeneity
d Upgraded to moderate-certainty level because of low bias (77% of the participants were from studies at low risk of bias), while heterogeneity can be explained by long
span of time between the first and the last study (1982 and 2017), The publication bias can be explained with the heterogeneity.
e Downgraded to very low-level certainty because, inconsistency, low bias and high heterogeneity
f Upgraded to moderate-certainty level because of narrow confidence intervals, consistency of direction of effect, no indirectness of evidence, low risk of bias, low
heterogeneity, no evidence of selective reporting.
g Upgraded to moderate-certainty level because the large effect size with precise narrow confidence interval, consistency of direction of effect, no indirectness of
evidence, and no heterogeneity and no evidence of selective reporting.
https://doi.org/10.1371/journal.pone.0237571.t006
PLOS ONE Preconception care of mothers with diabetes: Systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0237571 August 18, 2020 19 / 32
apparent publication bias in this outcome can be explained with the heterogeneity associated
with this analysis.
Maternal hypoglycemia. We are uncertain about the effect of PCC on maternal hypoglyce-
mia during the first trimester of pregnancy; (RR 1.38; 95% CI: 1.07–1.79); three studies; 686
women; very low-certainty evidence) (Fig 5) (Table 5). The grade of evidence was downgraded
from low to very low due to inconsistency of the direction of effect and high heterogeneity (I2
= 76%) in the included studies (Table 6). The true effect is likely to be substantially different
from the effect estimated in this review.
Preterm delivery. The results of the meta-analysis on the effect of PCC on preterm delivery
indicate that PCC lead to a slight reduction in preterm delivery rate among women with diabe-
tes (RR 0.85; 95% CI: 0.73–0.99; nine studies, 2414 women; moderate-certainty evidence) (Fig
6) (Table 5). We upgraded the body of evidence for the effect of PCC on the reduction of pre-
term delivery to moderate quality. This upgrade was based on the narrow confidence intervals
around the point estimate, consistency of direction of effect in most of the included studies, no
indirectness of evidence, low risk of bias of the body of evidence as only 1.9% of the partici-
pants were from one study with high risk of bias. The low heterogeneity with no evidence of
Fig 3. Risk ratio for congenital malformations from 25 studies of women with pre-existing diabetes mellitus who
did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g003
Fig 4. First trimester means values of glycosylated hemoglobin (HbA1c) from 24 studies of women with pre-
existing diabetes mellitus who did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g004
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selective reporting increase our confidence in the outcome of a small reduction in preterm
delivery (Fig 6, Table 6)
Perinatal mortality. The meta-analysis results on the effect of PCC on perinatal mortality
indicates that PCC results in a large reduction in perinatal mortality (RR 0.46; 95% CI: 0.30–
0.73; ten studies; 3071 women; moderate-certainty evidence) (Fig 7) (Table 5). The quality of
evidence has been upgraded to moderate due to the narrow confidence intervals, consistency
of direction of effect in most of the included studies, no indirectness of evidence, and low risk
of bias of the body of evidence as only 7.6% of the participants were from two studies at high
risk of bias and no heterogeneity or publication bias.
Small for gestational age. The result of the meta-analysis indicates that PCC may result in
large reduction in SGA (RR 0.52; 95% CI: 0.37–0.75; six studies, 2261 women; moderate-cer-
tainty evidence) (Fig 8) (Table 5). We upgraded the body of evidence for the effect of PCC on
the reduction of SGA to moderate-quality on account of the large effect size (48% reduction in
SGA) with precise narrow confidence interval, consistency of direction of effect throughout
the included studies, no indirectness of evidence, and no heterogeneity and no evidence of
selective reporting. We considered bias in the included studies as low (2% of the participants
were from one study at high risk of bias) (Fig 8, Table 6).
NICU admission. The result of the meta-analysis on the effect of PCC on admission to
NICU indicates that PCC may reduce the rate of NICU admissions (RR 0.75; 95% CI: 0.67–
0.84; four studies; 1322 women; moderate-certainty evidence) (Fig 9) (Table 5). The body of
evidence was upgraded owing to precise narrow confidence intervals, consistency of direction
of effect, no indirectness of evidence, and no heterogeneity and no evidence of selective report-
ing. We considered bias in the included studies as low.
Fig 5. Risk ratio for maternal hypoglycaemia from three studies of women with pre-existing diabetes mellitus who
did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g005
Fig 6. Risk ratio for preterm delivery from nine studies of women with pre-existing diabetes mellitus who did or
did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g006
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Other outcomes. Meta-analysis showed that the PCC may have little or no effect in reduc-
ing the CS rate (RR 1.02; 95% CI: 0.96–1.07; 14 studies; 3641 women; low-certainty evidence),
miscarriage rate (RR 0.86; 95% CI: 0.70–1.06; 11 studies; 2698 women; low- certainty evi-
dence), macrosomia rate, (RR 1.06; 95% CI: 0.97–1.15; nine studies; 2787 women, low- cer-
tainty evidence), neonatal hypoglycemia (RR 0.93; 95% CI: 0.74–1.18; five studies; 880 women;
low- certainty evidence), RDS (RR 0.78; 95% CI: 0.47–1.29; four studies; 466 women; very low-
certainty evidence) and shoulder dystocia (RR 0.28; 95% CI: 0.07–1.12; 2 studies; 530 women;
very low- certainty evidence).
Results of sensitivity analysis. We performed sensitivity analysis by excluding studies
with high risk of bias from the meta-analysis. Overall, results and conclusions were not
changed (Figs 1–7, S3 File).
Publication bias. We examined the possibility of publication bias by evaluating the asymme-
try of the Funnel Plots (Fig 10). Analysis of the effect of PCC on congenital malformations and
perinatal mortality (Fig 10A & 10B) demonstrated symmetrical distribution of the studies
which can reasonably exclude publication bias. Analysis of the effect on HbA1C, showed
asymmetrical distribution of the studies (Fig 10C), however this can be explained by the
marked heterogeneity associated with this outcome [69]. We found no evidence of selective
reporting of outcomes in all included studies.
Fig 7. Risk ratio for perinatal mortality from ten studies of women with pre-existing diabetes mellitus who did or
did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g007
Fig 8. Risk ratio for small for gestational age from six studies of women with pre-existing diabetes mellitus who
did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g008
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Discussion
The results of this review showed that PCC for mothers with pregestational diabetes is effective
in improving the outcomes for several maternal and neonatal complications associated with
pregestational diabetes. PCC results in a large reduction in congenital malformations. It proba-
bly results in a reduction of HbA1c in the first trimester of pregnancy, perinatal mortality and
in slightly earlier booking of mothers for antenatal care. PCC is likely to result in a slight
reduction of preterm birth rate. We are uncertain about the effect of PCC on maternal hypo-
glycemia during the first trimester of pregnancy.
Congenital malformations are one of the principal contributors to the high perinatal mor-
tality observed in pregnancies complicated with pregestational diabetes [7, 8, 70, 71]. Maternal
hyperglycemia at the time of organogenesis is the main teratogen [72, 73]. Evidence from clini-
cal and experimental studies showed that hyperglycemia leads to the production of reactive
oxygen species and depletion of antioxidants, which in turn causes intracellular oxidative
stress, cell injury and cell death at the time of organogenesis [74, 75]. It is not surprising that
PCC has a large effect on reducing the rate of congenital malformations as it provides the right
window of opportunity for optimum control of hyperglycemia before the early critical weeks
of conception and organogenesis. Another intervention with proven effectiveness in the pre-
vention of congenital malformations in this high-risk group is preconception folic acid supple-
mentation [76, 77]. Folic acid supplementation was part of almost all PCC interventions of the
studies included in this review and may have contributed to the large effect of PCC in reducing
congenital malformations rate.
The results of this review showed that women who received PCC achieved better control of
hyperglycemia compared to those who didn’t attend PCC as evident by the significantly lower
mean HbA1c level of the intervention group compared to the control group. Many studies
confirmed the incremental increase in the rate of adverse pregnancy outcomes, among women
with diabetes, with the increase in the level of HbA1c [78–81] and the significant risk reduc-
tion in congenital malformations with one percent reduction in HbA1c level [82].
The etiology of preterm birth is complex and many medical, socioeconomic, and psycho-
logical factors interplay in the causation of preterm delivery [83]. Nevertheless, mothers with
diabetes are at greater risk of preterm birth compared to the background population [6].
A recently published systematic review and modelling analysis of the global estimate of the
rate of preterm birth estimated that 14.84 million preterm live births were born in the year
2014, with the majority born in low- and middle-income countries [84]. Preterm birth is the
Fig 9. Risk ratio for neonatal intensive care unit admission from four studies of women with pre-existing diabetes
mellitus who did or did not receive preconception care.
https://doi.org/10.1371/journal.pone.0237571.g009
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Fig 10. Funnel plots for studies included in the meta-analysis for the effect of PCC on congenital anomalies (a),
perinatal mortality (b) and HbA1c (c).
https://doi.org/10.1371/journal.pone.0237571.g010
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leading cause of under-five mortality and one of the main causes of both short and long-term
morbidity [85, 86]. In addition, preterm birth is associated with high cost to the health system
and the families of the preterm born infant [87]. Based on the above account, the reduction in
the prevalence of preterm birth achieved by the attendance of PCC will have a considerable
impact on the perinatal mortality and neonatal and infant morbidity for children born to
mothers with pregestational diabetes. This assertion has been confirmed by the marked reduc-
tion in perinatal mortality and in the admission to NICU for infants of mothers who received
PCC compared to those who did not in this review.
The results of this review showed a significant reduction in the rate of SGA in women who
attended PCC. This effect maybe secondary to the significant reduction in congenital malfor-
mations rate. The association between SGA and congenital malformations, especially those for
the heart and the urinary tract, has been documented in published reports [88, 89]. Neverthe-
less, we cannot exclude the effect of healthy lifestyle promotion including smoking cessation,
weight control, and teratogenic drugs avoidance as part of many PCC programs, which are fac-
tors contributing to the reduction in the rate of SGA [90].
The effects of PCC on the reduction of congenital malformations, improved glycemic con-
trol in the first trimester of pregnancy, reduced preterm delivery, and SGA rate reflected posi-
tively on the substantial reduction of 54% in perinatal mortality rate in women who attended
PCC compared to those who did not (Fig 7, Table 6).
Meta-analysis results showed that the effect of PCC on maternal hypoglycemia was of very
low-certainty level. The three included studies had a low risk of bias but a high level of hetero-
geneity and inconsistency of direction of effect. Studies included were conducted in different
time periods, during which time many innovations were made in the management of diabetes,
which explains the heterogeneity level (S3 File, Fig 8). Direction, magnitude and certainty
about the effect of PCC on maternal hypoglycemia may change with conduction of additional
studies addressing this outcome”
We are not surprised that PCC had little or no effects on some outcomes such as macroso-
mia, shoulder dystocia and CS delivery rate, which may be influenced by perinatal care rather
than PCC. Similarly, PCC had no effect on miscarriage rate, this can be explained by the late
attendance of the control group for antenatal care by which time many events of miscarriage
had already occurred. This assumption is further supported by the significance of early book-
ing for antenatal care of the intervention group shown in this review.
Based on our previous systematic review results, an economic evaluation study found that
pregestational diabetes lifetime societal cost is $5.5 billion. However, the study did not evaluate
the cost of the recommended universal PCC and the amount of saving with such implementa-
tion [13]. Another recently published study [50] showed relatively low saving by provision of
PCC to diabetic women compared to routine care. This was explained by the improvement in
obstetrics care which may have attenuated potential savings in addition to the poor utilization
of PCC as only 40–60% of the target population attend the service [50]. It is worth noting that
these studies were conducted in high income countries which makes it difficult to generalize
the results to Low and Middle-Income Countries (LMICs) with different economic constrains
and health services provision.
In most settings, nearly 50% of pregnancies complicated with diabetes are unplanned,
hence this group of women are unlikely to attend PCC service [91–93]. Qualitative studies
which investigated the reasons behind poor utilization of PCC showed that women with diabe-
tes who did not attend PCC are more frequently unmarried, have modest education attain-
ment and are unemployed [94]. Other factors include lack of knowledge and attitude of
women with diabetes towards fertility, contraception, and the negative message about compli-
cations of diabetes in pregnancy rather than the benefits of PCC they tend to receive from
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healthcare providers [95]. However, nation-wide programs, which addressed many barriers to
the utilization of PCC, had moderate success in increasing attendance for PCC for women
with diabetes [50].
It is worth mentioning that all studies included in this review were conducted in high
income countries, which may have underestimated the effect of PCC on many outcomes con-
sidering the projected increased prevalence of pregestational diabetes in LMICs and the lim-
ited resources for antenatal and neonatal care.
Strengths and limitations
This review is a comprehensive assessment of all important maternal, perinatal outcomes
which could be improved by a variety of interventions in the preconception period. The review
included a large number of studies and participants. The use of the GRADE tool to evaluate
the body of evidence has improved our certainty about the effectiveness of PCC for the main
outcomes. The results of this review concur with previously published reviews on the effective-
ness of PCC [9, 16]. However, it provides higher quality of evidence with high certainty for the
main important outcomes indicating that further research is unlikely to change the conclusion
about the effectiveness of PCC in these outcomes.
We are aware of the limitations of this review including the uncertainty about the feasibility
and the applicability of PCC in LMICs, as all the included studies were conducted in high
income countries, especially if we consider the high cost of such programs. All the studies
which contributed data to this review are observational, which downgraded the body of evi-
dence from high to low before even considering other factors which affect the certainty about
the direction and size of the effect of intervention on the outcomes. However, it is unlikely to
conduct trials examining an intervention such as PCC because it is unethical to randomize dia-
betic women to receive or not to receive PCC. The only trial included in this review had major
biases because it allowed participants to shift between the intervention and the control groups,
hence the results lacked internal validity.
Implication to practice. New strategies for incorporating PCC in ongoing healthcare ser-
vices, such as adults’ diabetic clinics and primary healthcare may prove to be cost effective and
improve the feasibility and applicability of PCC globally.
Incorporation of health education about contraception, fertility of women with diabetes,
and the importance of pregnancy planning in the services of diabetic clinics may improve the
uptake of PCC.
Implication to research. Further research in interventions for improving pregnancy plan-
ning and increase utilization of PCC in different communities may improve our understand-
ing of the poor utilization of PCC and suggest areas for improvement. In addition, research to
investigate important outcomes, which are still surrounded by uncertainty, such as the associa-
tion between PCC and maternal hypoglycemia, should be encouraged. There is lack of studies
addressing these problems in low-income countries that raise the need for future research
both quantitative and qualitative.
Conclusion
PCC for women with pre-gestational type 1 or type 2 diabetes mellitus is effective in improving
rates of congenital malformations. In addition, it may improve the risk of preterm delivery
and admission to NICU. PCC probably reduces maternal HbA1C in the first trimester of preg-
nancy, perinatal mortality and SGA. There is uncertainty regarding the effects of PCC on early
booking for antenatal care or maternal hypoglycemia during the first trimester of pregnancy.
PCC has little or no effect on other maternal and perinatal outcomes.
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